---
title: "Acute Kidney Injury"
---
# Acute Kidney Injury
`disease · renal injury · inflammation · oxidative stress · STING pathway · high mortality`

Last modified 2026-06-04 · 5 papers · 11 incoming links

| | |
|---|---|
| **Type** | Clinical disease / Renal injury |
| **Key mechanism** | STING-mediated type I interferon signaling |
| **Pathogenic pathways** | Oxidative stress, macrophage dysfunction, mitochondrial impairment |
| **Hub genes** | [[aco2]], [[fbp1]], [[pfkl]] |
| **STING inhibitor** | [[ksi-028]] |
| **Nanoplatform** | [[rgd-ceo2-quercetin]] |
| **CI-AKI incidence** | 10.53% (92% under-diagnosed) |
| **Postoperative AKI (CKD)** | 24.2% |
| **Papers** | 5 indexed |

---

**Acute kidney injury (AKI)** is a clinical syndrome characterized by rapid decline in renal function, high morbidity, and mortality with currently limited effective treatments. At the molecular level, excessive activation of the [[sting|STING]] pathway drives aberrant type I interferon signaling and inflammatory responses that initiate and propagate kidney injury.¹ Beyond inflammation, AKI pathogenesis involves multiple interconnected mechanisms including oxidative stress overload, aberrant macrophage polarization, mitochondrial dysfunction, and impaired renal tubular epithelial cell energy metabolism.² Three hub genes — [[aco2]], [[fbp1]], and [[pfkl]] — emerge as central regulatory nodes in these pathological pathways via integrated transcriptomic and network pharmacology analyses.² The clinical burden is substantial: contrast-induced AKI (CI-AKI) represents the third most common hospital-acquired kidney injury with a 10.53% incidence yet remains under-diagnosed in over 92% of cases, while postoperative AKI complicates 24.2% of surgical patients with pre-existing [[chronic-kidney-disease|chronic kidney disease (CKD)]].³⁴

---

## Mechanism

[[Sting|STING]]-mediated activation of type I interferon signaling represents a central pathogenic driver of AKI. Aberrant STING activation in damaged renal tissue triggers excessive production of pro-inflammatory cytokines and interferon-beta, perpetuating the inflammatory cascade that characterizes acute kidney injury.¹ This inflammatory milieu is complemented by three additional pathogenic mechanisms operating in concert. First, oxidative stress becomes overwhelming as reactive oxygen species accumulate beyond cellular buffering capacity, depleting antioxidant reserves and driving lipid peroxidation in renal tubular epithelial cells. Second, macrophage dysfunction emerges as polarized macrophages adopt a pro-inflammatory phenotype rather than promoting tissue repair and resolution of inflammation. Third, mitochondrial impairment manifests as loss of mitochondrial membrane potential, reduced ATP generation, and activation of mitochondrial apoptotic pathways, directly compromising the energy-dependent functions of renal tubular epithelial cells required for reabsorption and detoxification.²

The [[aco2|aconitase 2 (ACO2)]], [[fbp1|fructose-1,6-bisphosphatase 1 (FBP1)]], and [[pfkl|phosphofructokinase-liver (PFKL)]] hub genes orchestrate these pathological processes by regulating glycolysis and the citric acid cycle, thereby controlling both inflammatory responses and energy metabolism in injured renal tissue. Dysregulation of these metabolic hub genes drives the transition from compensatory metabolic adaptation to irreversible energy depletion and kidney dysfunction.²

---

## Clinical subtypes and epidemiology

Contrast-induced acute kidney injury (CI-AKI), defined as acute decline in renal function within 48 hours of iodinated contrast exposure during angiography, represents the third most common cause of hospital-acquired kidney injury. A comprehensive retrospective analysis of 3,437 angiography patients revealed a CI-AKI incidence of 10.53% (362 cases), yet strikingly only 7.73% of these cases were documented in discharge summaries, indicating a clinical under-diagnosis rate exceeding 92%.³ The key modifiable and non-modifiable risk factors for CI-AKI include reduced glomerular filtration rate (eGFR), low [[serum-albumin|serum albumin]] concentration, and elevated systemic [[leukocyte-count|leukocyte count]], which together comprise a high-risk phenotype susceptible to contrast-induced injury.

Postoperative AKI in patients with pre-existing [[chronic-kidney-disease|CKD]] represents another high-risk clinical phenotype. Among 3,851 surgical patients with CKD tracked in the MIMIC-IV database, postoperative AKI developed in 24.2% (932 patients), representing a substantial complication with accelerated chronic kidney disease progression.⁴ The clinical heterogeneity of postoperative AKI—spanning perioperative hypotension, intra-operative ischemia, and drug nephrotoxicity—underscores the need for patient-specific risk stratification before injury becomes irreversible.

---

## Therapeutic approaches

[[Sting|STING]] pathway inhibition has emerged as a rationally designed therapeutic strategy for AKI. [[Ksi-028|KSI-028]], a novel tetrahydroquinoline-based STING inhibitor, engages STING through a noncanonical, allosteric binding mode and potently suppresses STING-dependent type I interferon production and pro-inflammatory cytokine release in both murine and human renal cells. In a cisplatin-induced AKI mouse model, KSI-028 attenuated both renal and hepatic injury while simultaneously down-regulating STING-associated inflammatory gene expression, establishing the tetrahydroquinoline scaffold as a promising foundation for next-generation STING-driven kidney disease therapeutics.¹

Targeted nanoplatform approaches address the multifactorial pathogenesis of AKI by simultaneously modulating oxidative stress, macrophage polarization, and mitochondrial quality control. [[Rgd-ceo2-quercetin|RGD-CeO₂@Quercetin]] is a multifunctional nanoplatform composed of mesoporous hollow cerium dioxide conjugated to the RGD tripeptide ligand for integrin αvβ3-mediated targeting to injury-prone renal tissue. The cerium oxide nanocore scavenges reactive oxygen species and activates the [[nrf2|Nrf2]]/[[ho-1|HO-1]]/[[gpx4|GPX4]]/[[sod1|SOD1]] cytoprotective pathway, alleviating oxidative stress and reducing renal tubular epithelial cell apoptosis. The quercetin payload simultaneously promotes mitophagy—selective autophagy of damaged mitochondria—in renal tubular epithelial cells, restoring cellular bioenergetics and tissue repair capacity. In vivo studies demonstrated that this integrated nanoplatform improves renal function, ameliorates histological damage, and reduces inflammatory infiltration in AKI mouse models.⁵

Network pharmacology and molecular docking studies have identified three FDA-approved drugs—Ajmaline, Cimetidine, and Tretinoin—with strong binding affinities to the hub proteins ACO2, FBP1, and PFKL, suggesting therapeutic potential for drug repurposing in AKI treatment and supporting future mechanistic studies.²

---

## Risk prediction and early diagnosis

Machine learning approaches have substantially advanced AKI risk stratification, addressing the critical clinical bottleneck of late diagnosis and missed cases. In contrast-induced AKI prediction, nine machine learning models were developed using [[electronic-hospital-monitoring-system|electronic hospital monitoring]] data from 3,437 patients undergoing angiography.³ [[Logistic-regression|Logistic regression]] achieved the highest discriminative performance with an AUC of 0.806 and Brier score of 0.076, while linear support vector machine (LSVM) demonstrated comparable AUC of 0.807. Both models significantly outperformed the conventional Mehran score, the current clinical standard, establishing machine learning as superior for CI-AKI risk screening.

For postoperative AKI in CKD patients, the XGBoost machine learning model achieved an AUC of 0.844, accuracy of 79.1%, sensitivity of 79%, and F1-score of 0.73 on MIMIC-IV data, substantially exceeding conventional risk calculators.⁴ [[Lightgbm|LightGBM]] and Random Forest were the second- and third-ranked models, respectively. Explainability analysis using SHAP (Shapley Additive exPlanations) identified [[sofa-score|SOFA score]], estimated glomerular filtration rate (eGFR), systolic blood pressure, [[serum-albumin|serum albumin]], and serum phosphorus as the most influential predictors driving model predictions. Integration of these machine learning models with explainable artificial intelligence into [[electronic-hospital-monitoring-system|electronic hospital monitoring systems]] supports real-time clinical decision support, enabling transparent risk stratification and personalized perioperative care strategies.

---

## References
1. PMID:41999331 — Discovery of a new tetrahydroquinoline-based chemotype for STING inhibition with in vivo efficacy against acute kidney injury
2. PMID:42133161 — Unraveling the molecular landscape and therapeutic strategies for acute kidney injury: insights from transcriptomics, network pharmacology, virtual screening, and in vitro experiments
3. PMID:42056720 — In-hospital electronic monitoring system approaches to epidemiologic investigation and predictive modeling of contrast-induced acute kidney injury
4. PMID:42157597 — Machine learning-based risk prediction model for postoperative acute kidney injury in surgical patients with chronic kidney disease (CKD): development, validation, and SHAP-based explainability
5. PMID:41506100 — Nanoplatform for renal ischemia-reperfusion injury repair: modulating macrophage polarization, oxidative stress, and mitophagy